Samra B, Khoury JD, Morita K, et al. Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse. *Blood Adv*. 2021;5(20):3913-3918.

The visual abstract contained several errors that were introduced by the compositor in rebranding the image. The colors in the color legends were reversed. In the legends in the upper panels, "BL" should be indicated by a blue line and "HGBL" should be indicated by a red line. In the legend in the lower left panel, "No BM disease at Dx" should be indicated by a blue line, and "BM disease at Dx" should be indicated by a red line. In the legend in the lower right panel, "No CNS disease at Dx" should be indicated by a blue line and "CNS disease at Dx" should be indicated by a red line. Also, the numbers of patients at risk were incorrect. In the lower left graph, the P value for cumulative incidence of relapse for bone marrow (BM) disease vs no BM disease should be $P = 0.02$, not $P < 0.02$. In the y-axis labels of 3 of the graphs, "relapse" was misspelled.

The corrected visual abstract is shown below. The publisher apologizes for the errors, which have been corrected in the published article.